Citadel Advisors’s Alpha Tau Medical DRTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.44M Buy
193,800
+118,200
+156% +$1.07M ﹤0.01% 6117
2026
Q1
$534K Buy
75,600
+50,400
+200% +$356K ﹤0.01% 9140
2025
Q4
$125K Buy
+25,200
New +$106K ﹤0.01% 11465

Other funds holding DRTS

Citadel Advisors's DRTS Position: Q2 2026 in Review

Citadel Advisors increased its Alpha Tau Medical (DRTS) stake by 74% in Q2 2026, buying an estimated $238K and bringing the position to 61,559 shares worth $774K. The position accounts for ﹤0.01% of the portfolio, ranked #8832.

Citadel Advisors first reported a position in DRTS in Q1 2022 and has held it in 7 quarters since. 74 funds tracked by Wall St. Rank hold DRTS as of Q2 2026.

  • Citadel Advisors held 61,559 shares of Alpha Tau Medical worth $774K as of Q2 2026.
  • Citadel Advisors bought 26,164 Alpha Tau Medical shares in Q2 2026, an estimated $238K.
  • Alpha Tau Medical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8832 holding.
  • Citadel Advisors first reported a position in Alpha Tau Medical in Q1 2022 and has held it in 7 quarters since.
  • 74 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.